These four classes of drugs, though currently approved for treatment of PAH, are not approved for therapy in WHO groups 2–5 PH where these medications may cause harm in some cases (except for sGC which is also approved in WHO group 4 PH). The gene discussed is SGCB; the disease is pulmonary arterial hypertension.